drugset / Trial / NCT04564027
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
Timeline
- Start
- 2020-12-01
- Primary completion
- 2025-02-18
- Completion
- 2025-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceralasertib | Small molecule | 160 mg | Oral |